Exchange Traded Concepts LLC Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Exchange Traded Concepts LLC boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,119 shares of the specialty pharmaceutical company’s stock after purchasing an additional 560 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Supernus Pharmaceuticals were worth $800,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Stephens Investment Management Group LLC raised its holdings in shares of Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after acquiring an additional 33,710 shares during the last quarter. Pacer Advisors Inc. increased its holdings in shares of Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after purchasing an additional 403,028 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after purchasing an additional 74,438 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 1.1% in the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after purchasing an additional 7,833 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 14.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after purchasing an additional 91,354 shares during the last quarter.

Supernus Pharmaceuticals Stock Down 0.4 %

SUPN opened at $39.00 on Thursday. The firm has a market cap of $2.15 billion, a P/E ratio of 36.45 and a beta of 0.90. The business has a fifty day simple moving average of $37.04 and a 200-day simple moving average of $34.36. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.69.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals’s revenue was up 14.2% compared to the same quarter last year. During the same period last year, the business posted ($0.29) earnings per share. Sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,913 shares of company stock worth $5,687,914. Company insiders own 9.30% of the company’s stock.

Wall Street Analyst Weigh In

SUPN has been the subject of several recent research reports. Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target for the company. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.